Soft Tissue Sarcoma AdultNCT03134742
Radiation Effects on Bone
An observational study of Soft Tissue Sarcoma Adult, run by State University of New York - Upstate Medical University at 1 site in United States.
Trial summary
Post-radiotherapy fragility fractures (caused by weakened bones) are an occasional complication of orthopedic oncology of soft tissue sarcoma patients. Treatment for impending fracture due to radiotherapy does exist in the form of operative stabilization, to prevent the bone from breaking. Read more about this study
- Who is it for?
- Ages 18 to 89 years
- Conditions the study is for
- Soft Tissue Sarcoma Adult
- What is being tested?
- CT Scan, DEXA Scans and CT and DEXA Scans
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Mar 2017to 13 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects between the ages of 18 and 89 years of age, who have been diagnosed with soft tissue sarcoma of an extremity, who have not had radiotherapy treatment, or been diagnosed with metastatic carcinoma, atypical lipomatous tumors or low grade soft tissue sarcomas.
Who may be able to join
- Patients of Dr. Damron's being treated for soft tissue sarcoma of an extremity, who will undergone radiotherapy, and will follow with Dr. Damron for routine oncology surveillance with routine CT scans of the chest at minimum.
- Must be at least 18 years of age and no older than 89 years of age.
Who cannot join
- Patients who are treated with radiotherapy but who do not have soft tissue sarcoma, such as those with metastatic carcinoma,
- Patients who have soft tissue sarcoma who will not receive adjuvant radiotherapy, such as those with atypical lipomatous tumors or other low grade soft tissue sarcomas
- Patients who will not be obtaining their follow up CT studies at Upstate Bone and Joint Center-since the calibration phantom needs to be located in one central location.
- Incarcerated patients
- Patients younger than 18 years of age
Trial locations and contacts
1 site in 1 country.
United States1 site
SUNY Upstate Medical University
Syracuse, New York, 13210
About this study
Official title: Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone
Post-radiotherapy fragility fractures (caused by weakened bones) are an occasional complication of orthopedic oncology of soft tissue sarcoma patients. Treatment for impending fracture due to radiotherapy does exist in the form of operative stabilization, to prevent the bone from breaking. Without the ability to predict those patients at a higher risk for fracture, indications for treatment are difficult to determine. This study is to determine if there is a correlation between patients undergoing radiotherapy for soft tissue sarcoma and loss of bone density. The study wll evaluate bone loss for short and long term fracture prediction using dual-energy xray, absorptiometry (DEXA [DXA]) and computerized tomography scans (CT Scans)
Read the detailed description
Post-radiotherapy fragility fractures are a frequent complication of orthopedic oncology care of sarcoma patients, who often receive radiotherapy (XRT) as adjunctive treatment. Prediction of these fractures is difficult as there has been no demonstrable relationship shown, to date, between bone density and fracture risk for this population. Treatment for an impending fracture due to radiotherapy does exist in the form of prophylactic operative stabilization with an intramedullary nail to prevent the bone from breaking. Without the ability to predict those patients at higher risk for fracture, clinical indications for prophylactic treatment are difficult to develop.
Bone density has been investigated as a possible fracture prediction tool. Work by Dhakal et al. suggested specifically that bone density, as measured by dual-energy x-ray absorptiometry (DXA), of the irradiated limb is not decreased following therapeutic doses of radiotherapy (50 Gy) administered for soft tissue sarcomas. However, their technique did not measure pre-radiotherapy bone mineral density (BMD), but rather compared post-radiotherapy BMD of the irradiated site to contralateral and ipsilateral non-irradiated long bones of the extremity. While this technique accounted for disuse osteopenia (bone loss due to decreased use of the afflicted limb), it did not account for any systemic effects of radiation therapy. This is important, because largely based on their work, BMD has not been utilized as a predictor of risk of fracture, and other measures have been sought for this particular clinical situation without success. Others have also failed to show decreased BMD within the irradiated field. However, these studies have either lacked power to show statistical significance or the patient population was pediatric, a growing population in which age related accrual of bone density was a potential confounder.
What Dhakal and others did not account for was the possibility of abscopal (systemic) effects of radiotherapy that might also affect the contralateral and distant sites. Recent work in this investigators laboratory and others using small animal models has suggested that radiation to one limb has statistically significant effects on the contralateral limb in terms of decreased bone mineral density and loss of bone strength. The importance and clinical implications of such an abscopal effect is as of yet unclear. At the very least, its presence calls into question the conclusion that bone density is not decreased at the site of radiation, since differences may only be able to be shown when compared to non-irradiated control subjects. Moreover, there may be an adverse effect on distant bones, further lowering BMD and contributing to fragility fractures, particularly in post-menopausal women who are already at some increased risk. There is mixed clinical data on this topic, with one series of 45,662 prostate cancer patients showing a 76% increased risk of hip fracture (regional bone) following pelvic radiation, but no increased risk of fractures outside the field of radiation in three studies of patients with pelvic radiation for cervical and other female cancers or prostate cancer.
The investigators of this study propose to determine whether human subjects undergoing radiotherapy for soft tissue sarcomas exhibit for abscopal bone loss. Patients in the PI's (Dr. Damron) practice obtain baseline-staging studies, including computerized tomography (CT) of the chest/abdomen/pelvis prior to treatment. Post-treatment, patients then undergo oncology surveillance utilizing routine repetitive computerized tomography of the chest and sometimes of the abdomen/pelvis for a subset where the baseline abdomen/pelvis CT scans show abnormalities that need to be followed. These CT scans, when combined with calibration phantoms of known density, afford a prime opportunity to quantify bone mineral density based on those scans at sites distant to the primary site of radiotherapy (typically in the extremity).
This project will also evaluate a secondary aim, that of comparing effectiveness of utilization of CT vs BMD as a tool to evaluate bone loss in short term with a potential for long term fracture prediction in this patient population. In order to accomplish this aim, simultaneously, in a subset of patients who give consent for non-standard of care DXA scans, the investigators will evaluate the potential abscopal bone loss by assessing changes in BMD as measured by DXA, a tool that is a gold standard for bone density evaluation and for fracture prediction in routine clinical practice. The investigators will compare BMD pre- and post-radiotherapy at the site of irradiation, and further compare this change to that of the change in BMD at distant sites.
- Conditions
- Soft Tissue Sarcoma Adult
- Being tested
- Control Group, CT Scan, DEXA Scans, CT and DEXA Scans
- Keywords
- soft tissue sarcoma extremities
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Control GroupOther
No interventions this is the control group-no additional scans
CT ScanDiagnostic test
CT Scan of affected and contralateral limb
DEXA ScansDiagnostic test
DEXA Scan of affected and contralateral limb
CT and DEXA ScansDiagnostic test
CT Scan and DEXA Scan of affected and contralateral limb
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison Receives: Other: Control Group | |
| CT Scan only | Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment. Receives: Diagnostic Test: CT Scan | |
| DEXA Scans only | Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment Receives: Diagnostic Test: DEXA Scans | |
| CT and DEXA Scans | Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment Receives: Diagnostic Test: CT and DEXA Scans |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine whether subjects undergoing radiotherapy for soft tissue sarcoma exhibit abscopal bone loss
CT Scans combined with calibration phantoms will be used to quantify bone density, when compare pre- and post-radiotherapy at the site of irradiation and at distant sites (contralateral limb)
Measured: 12 months post radiation
Secondary outcomes (1)
Comparing effectiveness of utilization of CT vs DEXA as a tool to evaluate bone loss in short term with potential for long term fracture prediction
DEXA Scans will be used to evaluate the potential abscopal bone loss by assessing changes in bone mineral density as measured by DEXA, when compared pre- and post-radiotherapy at the site of irradiation and at distant sites (contralateral limb)
Measured: 12 months post radiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2017
- Study start13 Mar 2017
- Primary completion13 Apr 2025 (estimated)
- Study completion13 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Soft Tissue Sarcoma AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- State University of New York - Upstate Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Timothy Damron, M.D., State University of New York - Upstate Medical University
- Investigators
- Timothy Damron, MD, Principal investigator, State University of New York - Upstate Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03134742
- Sponsor's protocol ID
- 1019460
- Status last verified
- Nov 2023
- First submitted
- 26 Apr 2017
- Last updated
- 21 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone
- ClinicalTrials.gov ID
- NCT03134742
- Acronym / sponsor ID
- 1019460
- Conditions
- Soft Tissue Sarcoma Adult
- Keywords
- soft tissue sarcoma extremities
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- State University of New York - Upstate Medical UniversityUniversity, hospital or other
- Study start
- 13 Mar 2017 (actual)
- Primary completion
- 13 Apr 2025 (estimated)
- Study completion
- 13 Apr 2025 (estimated)
- First posted
- 1 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Post-radiotherapy fragility fractures (caused by weakened bones) are an occasional complication of orthopedic oncology of soft tissue sarcoma patients. Treatment for impending fracture due to radiotherapy does exist in the form of operative stabilization, to prevent the bone from breaking. Without the ability to predict those patients at a higher risk for fracture, indications for treatment are difficult to determine. This study is to determine if there is a correlation between patients undergoing radiotherapy for soft tissue sarcoma and loss of bone density. The study wll evaluate bone loss for short and long term fracture prediction using dual-energy xray, absorptiometry (DEXA [DXA]) and computerized tomography scans (CT Scans)
Detailed description
Post-radiotherapy fragility fractures are a frequent complication of orthopedic oncology care of sarcoma patients, who often receive radiotherapy (XRT) as adjunctive treatment. Prediction of these fractures is difficult as there has been no demonstrable relationship shown, to date, between bone density and fracture risk for this population. Treatment for an impending fracture due to radiotherapy does exist in the form of prophylactic operative stabilization with an intramedullary nail to prevent the bone from breaking. Without the ability to predict those patients at higher risk for fracture, clinical indications for prophylactic treatment are difficult to develop.
Bone density has been investigated as a possible fracture prediction tool. Work by Dhakal et al. suggested specifically that bone density, as measured by dual-energy x-ray absorptiometry (DXA), of the irradiated limb is not decreased following therapeutic doses of radiotherapy (50 Gy) administered for soft tissue sarcomas. However, their technique did not measure pre-radiotherapy bone mineral density (BMD), but rather compared post-radiotherapy BMD of the irradiated site to contralateral and ipsilateral non-irradiated long bones of the extremity. While this technique accounted for disuse osteopenia (bone loss due to decreased use of the afflicted limb), it did not account for any systemic effects of radiation therapy. This is important, because largely based on their work, BMD has not been utilized as a predictor of risk of fracture, and other measures have been sought for this particular clinical situation without success. Others have also failed to show decreased BMD within the irradiated field. However, these studies have either lacked power to show statistical significance or the patient population was pediatric, a growing population in which age related accrual of bone density was a potential confounder.
What Dhakal and others did not account for was the possibility of abscopal (systemic) effects of radiotherapy that might also affect the contralateral and distant sites. Recent work in this investigators laboratory and others using small animal models has suggested that radiation to one limb has statistically significant effects on the contralateral limb in terms of decreased bone mineral density and loss of bone strength. The importance and clinical implications of such an abscopal effect is as of yet unclear. At the very least, its presence calls into question the conclusion that bone density is not decreased at the site of radiation, since differences may only be able to be shown when compared to non-irradiated control subjects. Moreover, there may be an adverse effect on distant bones, further lowering BMD and contributing to fragility fractures, particularly in post-menopausal women who are already at some increased risk. There is mixed clinical data on this topic, with one series of 45,662 prostate cancer patients showing a 76% increased risk of hip fracture (regional bone) following pelvic radiation, but no increased risk of fractures outside the field of radiation in three studies of patients with pelvic radiation for cervical and other female cancers or prostate cancer.
The investigators of this study propose to determine whether human subjects undergoing radiotherapy for soft tissue sarcomas exhibit for abscopal bone loss. Patients in the PI's (Dr. Damron) practice obtain baseline-staging studies, including computerized tomography (CT) of the chest/abdomen/pelvis prior to treatment. Post-treatment, patients then undergo oncology surveillance utilizing routine repetitive computerized tomography of the chest and sometimes of the abdomen/pelvis for a subset where the baseline abdomen/pelvis CT scans show abnormalities that need to be followed. These CT scans, when combined with calibration phantoms of known density, afford a prime opportunity to quantify bone mineral density based on those scans at sites distant to the primary site of radiotherapy (typically in the extremity).
This project will also evaluate a secondary aim, that of comparing effectiveness of utilization of CT vs BMD as a tool to evaluate bone loss in short term with a potential for long term fracture prediction in this patient population. In order to accomplish this aim, simultaneously, in a subset of patients who give consent for non-standard of care DXA scans, the investigators will evaluate the potential abscopal bone loss by assessing changes in BMD as measured by DXA, a tool that is a gold standard for bone density evaluation and for fracture prediction in routine clinical practice. The investigators will compare BMD pre- and post-radiotherapy at the site of irradiation, and further compare this change to that of the change in BMD at distant sites.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control Group | – | Other: Control GroupSubjects will not have any additional scans only those that are standard of care. Their data will be used for comparison |
| CT Scan only | – | Diagnostic Test: CT ScanThree CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment. |
| DEXA Scans only | – | Diagnostic Test: DEXA ScansThree DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment |
| CT and DEXA Scans | – | Diagnostic Test: CT and DEXA ScansThree CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment |
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects between the ages of 18 and 89 years of age, who have been diagnosed with soft tissue sarcoma of an extremity, who have not had radiotherapy treatment, or been diagnosed with metastatic carcinoma, atypical lipomatous tumors or low grade soft tissue sarcomas.
Key inclusion criteria (2 listed)
- Patients of Dr. Damron's being treated for soft tissue sarcoma of an extremity, who will undergone radiotherapy, and will follow with Dr. Damron for routine oncology surveillance with routine CT scans of the chest at minimum.
- Must be at least 18 years of age and no older than 89 years of age.
Key exclusion criteria (5 listed)
- Patients who are treated with radiotherapy but who do not have soft tissue sarcoma, such as those with metastatic carcinoma,
- Patients who have soft tissue sarcoma who will not receive adjuvant radiotherapy, such as those with atypical lipomatous tumors or other low grade soft tissue sarcomas
- Patients who will not be obtaining their follow up CT studies at Upstate Bone and Joint Center-since the calibration phantom needs to be located in one central location.
- Incarcerated patients
- Patients younger than 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Control GroupNo interventions this is the control group-no additional scans | Other | Control Group |
| CT ScanCT Scan of affected and contralateral limb | Diagnostic test | CT Scan only |
| DEXA ScansDEXA Scan of affected and contralateral limb | Diagnostic test | DEXA Scans only |
| CT and DEXA ScansCT Scan and DEXA Scan of affected and contralateral limb | Diagnostic test | CT and DEXA Scans |
Primary outcome
Determine whether subjects undergoing radiotherapy for soft tissue sarcoma exhibit abscopal bone loss
Time frame: 12 months post radiation
CT Scans combined with calibration phantoms will be used to quantify bone density, when compare pre- and post-radiotherapy at the site of irradiation and at distant sites (contralateral limb)
1 secondary outcome
Comparing effectiveness of utilization of CT vs DEXA as a tool to evaluate bone loss in short term with potential for long term fracture prediction
Time frame: 12 months post radiation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for Soft Tissue Sarcoma Adult
RecruitingPhase 3
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Osteosarcoma, Pediatric Osteosarcoma
RecruitingPhase 1
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
RecruitingPhase 2
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Sarcoma,Soft Tissue
Active, not recruitingPhase 2
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Active, not recruitingPhase 1
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Adult Solid Neoplasm, Bladder Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Timothy Damron, MD principal investigator
State University of New York - Upstate Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Soft Tissue Sarcoma Adult, run by State University of New York - Upstate Medical University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine whether subjects undergoing radiotherapy for soft tissue sarcoma exhibit abscopal bone loss (time frame: 12 months post radiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2023.